OTCQB: PHRRF | CSE: PHRM
PharmaTher Holdings Ltd. Ketamine
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT

News

11/1/2021

PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics

 

Read More

10/27/2021

PharmaTher Provides Busines Update and Releases Financial Results for the First Quarter of Fiscal 2022

 

Read More

10/27/2021

World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor

 

Read More

10/19/2021

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

 

Read More

10/13/2021

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

 

Read More

10/6/2021

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

 

Read More

9/29/2021

PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor

 

Read More

9/28/2021

PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors

 

Read More

9/24/2021

PHARMATHER ANNOUNCES CAD$10 MILLION PRIVATE PLACEMENT WITH INSTITUTIONAL INVESTORS

 
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATE

Read More

9/21/2021

PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund

 

Read More

9/13/2021

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

 

Read More

9/9/2021

PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference

 

Read More

9/7/2021

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021

 

Read More

8/4/2021

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis

 

Read More

7/21/2021

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

 

Read More
Previous
Forward

    Archives

    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020

    Categories

    All

    RSS Feed

Psychedelic Pharmaceuticals

COMPANY  /  RESEARCH  /  INVESTORS  /  NEWS  /  CONTACT
Publicly-traded on the OTCQB: PHRRF and CSE: PHRM
© COPYRIGHT 2022.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.